ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) VP Meredith Cook sold 400 shares of the stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $63.33, for a total value of $25,332.00. Following the sale, the vice president now directly owns 80,545 shares in the company, valued at $5,100,914.85. This trade represents a 0.49 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Meredith Cook also recently made the following trade(s):
- On Thursday, February 13th, Meredith Cook sold 400 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $59.54, for a total value of $23,816.00.
- On Monday, January 13th, Meredith Cook sold 400 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $53.92, for a total value of $21,568.00.
ANI Pharmaceuticals Stock Up 1.7 %
Shares of ANIP opened at $62.49 on Friday. The business’s 50 day moving average is $58.26 and its 200 day moving average is $58.13. The company has a market capitalization of $1.36 billion, a PE ratio of -113.62 and a beta of 0.62. ANI Pharmaceuticals, Inc. has a 12-month low of $52.50 and a 12-month high of $70.81. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52.
Institutional Trading of ANI Pharmaceuticals
Analyst Upgrades and Downgrades
Several research analysts have issued reports on the company. StockNews.com raised ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday. HC Wainwright reissued a “buy” rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a research report on Monday, March 3rd. Leerink Partners assumed coverage on ANI Pharmaceuticals in a research report on Wednesday, December 11th. They issued an “outperform” rating and a $80.00 target price on the stock. Jefferies Financial Group assumed coverage on ANI Pharmaceuticals in a research report on Friday. They issued a “buy” rating and a $80.00 target price on the stock. Finally, Leerink Partnrs raised ANI Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, December 11th. Two equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $79.78.
Read Our Latest Report on ANI Pharmaceuticals
ANI Pharmaceuticals Company Profile
ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.
Read More
- Five stocks we like better than ANI Pharmaceuticals
- What Are Treasury Bonds?
- Why Costco Stock Is Poised to Hit $1,000 Again Soon
- How to Calculate Stock Profit
- MarketBeat Week in Review – 03/10 – 03/14
- How to Invest in Blue Chip Stocks
- Rubrik Stock’s V-Bottom Reversal Signals a Major Rally Ahead
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.